Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Go back to Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
(NASDAQ: ETON) Delayed: 58.45 -1.45 (2.42%)
Previous Close $59.90    52 Week High
Open $59.87    52 Week Low
Day High $59.95    P/E N/A 
Day Low $56.93    EPS
Volume 521,574